Literature DB >> 23111335

A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells.

Rajib Ghosh1, Lalithya C Singh, Jason M Shohet, Preethi H Gunaratne.   

Abstract

Lack of affordable technologies for delivering microRNAs and siRNAs into cells on a large scale has hindered our efforts to rapidly parse through hundreds of dysregulated genes/microRNAs in order to identify drivers of complex diseases. The instability and polyanionic nature of naked microRNAs impede efficient cellular uptake and reduce half-life. Viral delivery requires cloning, microRNA mimics/inhibitors require costly modifications, and both require toxic lipofection or electroporation. To address these challenges, we developed a robust method for delivering unmodified microRNAs into cells on cysteamine-functionalized gold nanoparticles (AuNPs). We validated our method in two different tumor models and found that the best formulation of miR(1)-AuNP(10)-S-PEG(0.5) had the highest payload (10-20 fold higher than lipofection), lowest toxicity (98% of cell viability following treatment), efficient uptake (96% of cells took it), fastest endosomal escape and increased half-lives (at least 5 days) impacting cell proliferation and patterns of target gene expression.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23111335     DOI: 10.1016/j.biomaterials.2012.10.023

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  45 in total

Review 1.  In vivo delivery of miRNAs for cancer therapy: challenges and strategies.

Authors:  Yunching Chen; Dong-Yu Gao; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2014-05-22       Impact factor: 15.470

2.  Research perspectives: gold nanoparticles in cancer theranostics.

Authors:  Junjie Li; Sanjay Gupta; Chun Li
Journal:  Quant Imaging Med Surg       Date:  2013-12

3.  Detection of plasmonic nanoparticles with full field-OCT: optical and photothermal detection.

Authors:  Amir Nahas; Mariana Varna; Emmanuel Fort; A Claude Boccara
Journal:  Biomed Opt Express       Date:  2014-09-11       Impact factor: 3.732

4.  Overcoming obstacles in microRNA delivery towards improved cancer therapy.

Authors:  Dikla Ben-Shushan; Ela Markovsky; Hadas Gibori; Galia Tiram; Anna Scomparin; Ronit Satchi-Fainaro
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

Review 5.  miRNA nanotherapeutics for cancer.

Authors:  Aditya Ganju; Sheema Khan; Bilal B Hafeez; Stephen W Behrman; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Drug Discov Today       Date:  2016-11-01       Impact factor: 7.851

Review 6.  Therapeutic prospects of microRNAs in cancer treatment through nanotechnology.

Authors:  Rajendra Awasthi; Michael John Rathbone; Philip Michael Hansbro; Mary Bebawy; Kamal Dua
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

7.  Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model.

Authors:  L D'Abundo; E Callegari; A Bresin; A Chillemi; B K Elamin; P Guerriero; X Huang; E Saccenti; E M A A Hussein; F Casciano; P Secchiero; G Zauli; G A Calin; G Russo; L J Lee; C M Croce; G Marcucci; S Sabbioni; F Malavasi; M Negrini
Journal:  Oncogene       Date:  2017-08-07       Impact factor: 9.867

Review 8.  Nanoscale delivery systems for microRNAs in cancer therapy.

Authors:  Sanda Boca; Diana Gulei; Alina-Andreea Zimta; Anca Onaciu; Lorand Magdo; Adrian Bogdan Tigu; Calin Ionescu; Alexandru Irimie; Rares Buiga; Ioana Berindan-Neagoe
Journal:  Cell Mol Life Sci       Date:  2019-10-21       Impact factor: 9.261

Review 9.  MicroRNAs in lung cancer.

Authors:  Pooja Joshi; Justin Middleton; Young-Jun Jeon; Michela Garofalo
Journal:  World J Methodol       Date:  2014-06-26

Review 10.  Progress in microRNA delivery.

Authors:  Yu Zhang; Zaijie Wang; Richard A Gemeinhart
Journal:  J Control Release       Date:  2013-09-25       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.